Eli Lilly CDR (LLY)
TSX
42.02
+0.31 (+0.74%)
Closed
Oct 9, 2026
Day's Range
41.2342.02
52 wk Range
28.7746.26
Financial Statements - LLY - Eli Lilly CDR
Revenue
65.17B▲ 5.9%
Net Income
20.64B▲ 42.6%Net Margin 31.7%
EBITDA
35.08B▲ 32.2%
Free Cash Flow
5.96B▲ 953.1%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Sales | 65.17B | 61.57B |
| Cost of Goods | 11.05B | 11.50B |
| Gross Profit | 54.12B | 50.06B |
 Operating Expense | - | - |
| Operating Income | 29.69B | 23.29B |
| Non-Operating Interest | - | - |
| Other Income Expense | -3.96B | -5.13B |
| Pre Tax Income | 25.73B | 17.33B |
| Income Tax | 5.09B | 2.85B |
| Net Income | 20.64B | 14.47B |
| EPS Basic | 0.629212 | 0.321852 |
| EPS Diluted | 0.626031 | 0.319426 |
| Basic Shares Outstanding | 32.80B | 44.97B |
| Diluted Shares Outstanding | 32.80B | 44.97B |
| Ebit | 29.69B | 18.40B |
| Ebitda | 35.08B | 26.54B |
| Net Income Continuous Operations | 20.64B | 14.47B |
| Minority Interests | - | - |
| Preferred Stock Dividends | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
